Evidence map›Paper›PMID 33543377›Full record

ReviewMedical oncology (Northwood, London, England)2021

Is there any place for novel agents in treating biliary tract cancer?

Gianluca Perego, Valentina Burgio, Renata Nozza, Giorgia Longobardo, Marco Bernecich, Andrea Luciani, Fausto Petrelli

Abstract readReview
PubMed Publisher
In one paragraph

Review in Medical oncology (Northwood, London, England), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 51% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Gianluca PeregoPharmacy Unit, IRCCS San Raffaele Hospital, Milan, Italy. gianperec@gmail.com.ORCID http://orcid.org/0000-0002-4309-4946
Valentina BurgioOncology Unit, IRCCS San Raffaele Hospital, Milan, Italy.
Renata NozzaSchool of Hospital Pharmacy, University of Milan, Milan, Italy.
Giorgia LongobardoPharmacy Unit, IRCCS San Raffaele Hospital, Milan, Italy.
Marco BernecichSchool of Hospital Pharmacy, University of Milan, Milan, Italy.
Andrea LucianiOncology Unit, ASST Bergamo Ovest, Treviglio, Italy.
Fausto PetrelliOncology Unit, ASST Bergamo Ovest, Treviglio, Italy.
Vita-Salute San Raffaele University · ITAzienda Ospedaliera Treviglio · ITUniversity of Milan · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Biliary tract cancer is an uncommon cancer in developed countries. In localized stages, surgery is the cornerstone of treatment with curative purpose. Conversely in advanced stages, chemotherapy with platinum-gemcitabine combination is the standard of care. Biliary tract cancers are a biologically heterogeneous group of malignancies, which perhaps explains the failure of targeted therapies in unselected patient populations to demonstrate benefit in advanced disease, although there are promises in selected populations (e.g. PD1/PD-L1 positive, BRAF

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsBiliary Tract NeoplasmsClinical Trials as TopicErb-b2 Receptor Tyrosine KinasesHumansImmune Checkpoint InhibitorsProtein Kinase InhibitorsERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesImmune Checkpoint InhibitorsProtein Kinase InhibitorsBiliary tract cancerImmunotherapyNovel agentsTargeted therapyTyrosine-kinase inhibitors

Identifiers

PMID33543377
OpenAlexW3128393907

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.